The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Bob Azelby, chief executive officer will be departing the Company and the Board imminently.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.29 USD | -4.27% | +0.73% | +207.04% |
May. 15 | Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
+207.04% | 247M | |
+18.34% | 124B | |
+15.06% | 109B | |
-6.39% | 23.84B | |
+2.39% | 22.42B | |
-12.11% | 17.5B | |
-41.64% | 16.43B | |
-12.07% | 16.61B | |
+1.05% | 13.4B | |
+25.87% | 11.47B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc